Is "colorectal cancer" rising in "young people"?

Interpretation of Cancer Trends

• Commenters note the article’s nuance: early-onset colorectal cancer (CRC) is up relative to past cohorts, but overall age‑adjusted cancer incidence and mortality have declined.
• Some stress this is not “all cancers” but specific ones; others highlight that several cancers show cohort effects in newer generations.
• A few raise Simpson’s paradox and question how age grouping and time slicing affect perceived trends.
• Questions arise about whether improved detection or changes in cause‑of‑death coding contribute, but rising deaths in younger groups are cited as evidence it’s not just more testing—though this point is contested.

Screening Strategies and Guidelines

• Strong encouragement to undergo screening, especially with family history, UC/IBD, or symptoms.
• Multiple options discussed: colonoscopy (gold standard + polyp removal), sigmoidoscopy, FIT/FIT‑DNA (e.g., Cologuard), and “poop in a box” tests.
• Some doctors recommend stool tests from 40 and colonoscopy at 45–50; others push colonoscopies earlier based on personal or family experience.
• One thread emphasizes risk‑adjusted, probabilistic decisions rather than one‑size‑fits‑all guidelines.

Risks, Complications, and Safety

• Colonoscopy is described as very common and generally safe but not risk‑free: perforation, bleeding, cardiovascular/respiratory events, and rare deaths are debated.
• Several anecdotes of serious complications (perforations, temporary stoma, large bills) contrast with many reports of uneventful procedures.
• Debate over complication rates: some cite figures on perforation and other adverse events per 10,000 procedures; others call high numbers implausible or misinterpreted.
• Concerns about over‑screening and harm from false positives are raised.

Anesthesia and Prep Experience

• Many say the procedure itself is easy; the bowel prep (large‑volume laxatives, fasting, frequent bathroom trips) is “the worst part.”
• Detailed practical tips: low‑fiber diet before, chilled or flavored prep, pill‑based regimens where appropriate, skin creams, scheduling time off work.
• Several people choose minimal or no sedation, reporting tolerable discomfort and faster recovery; others prefer deep sedation/twilight for comfort.

Cost, Insurance, and Classification

• US commenters report high out‑of‑pocket costs, especially on high‑deductible plans or when a screening becomes “diagnostic.”
• Clarifications: “preventive” colonoscopies in a certain age band can be zero‑cost under ACA rules; once there are symptoms or abnormal prior tests, the same procedure may be billed differently.
• Confusion between “covered” vs “covered at zero cost” is highlighted.

Symptoms and Diagnostic Delays

• Recurrent themes: rectal bleeding, changes in bowel habits, anemia, unexplained constipation, or visible blood that were initially dismissed, then later led to colonoscopy.
• Several anecdotes of young or middle‑aged people diagnosed at stage 2–4, often after being told to wait until 50 or after ignoring “minor” symptoms.
• Some suggest, pragmatically, that reporting blood in stool may be the only way to obtain earlier colonoscopy in rigid systems.

Diet, Lifestyle, and Environment

• Multiple commenters suspect modern diet and environment: processed foods, additives (emulsifiers, methyl cellulose), PFAS, herbicides, pollution, microplastics, and canned‑food linings.
• Others describe major dietary overhauls: high fiber, reduced red meat, minimal alcohol, low saturated fat, avoiding ultra‑processed foods, and report weight loss and better labs.
• Some note that many young CRC patients lack obvious lifestyle risk factors; hypotheses mentioned include long‑distance running (bowel ischemia), chronic inflammation, and microbiome factors like colibactin‑producing bacteria.
• Plant‑based diets are discussed, with distinctions between “healthy” and ultra‑processed vegan foods.

Statistical and Methodological Questions

• Several ask how incidence “per 100,000” is computed and whether reductions in other-cause mortality bias cancer rates.
• Others point out that more aggressive screening can increase both diagnoses and “deaths from X” via treatment harms and overdiagnosis.
• There is disagreement over how much apparent increase in young‑onset CRC reflects real risk versus detection, coding, and cohort artifacts; commenters flag this as unresolved.